Scholarlink

<p><i>Escherichia coli</i> (<i>E. coli</i>) is a leading cause of urinary tract infections (UTIs) and diabetic foot ulcers, especially in individuals with weakened immune systems. Pathogenic strains (PEC) employ virulence genes including <i>fimH</i>, <i>hlyA</i>, <i>usp</i>, <i>traT</i>, and <i>papC</i> to establish infection, evade immune responses, and cause tissue damage. However, despite its clinical significance, there is a lack of integrative studies profiling virulence genes and identifying mutations in PEC, which may contribute to pathogenicity, antimicrobial resistance, and limitations in targeted therapy. In this study, 210 <i>E. coli</i> isolates were collected from diabetic patients with UTIs or foot ulcers at Hayatabad Medical Complex (HMC), Peshawar. Identification was performed through biochemical profiling and confirmed via PCR targeting 16S rRNA. Antibiotic resistance was assessed using the Kirby-Bauer disk diffusion method. The presence of virulence genes was detected by PCR, and sequencing data were analyzed using bioinformatics tools such as Multiple Sequence Alignment, PROVEAN, InterProScan, and SWISS-MODEL. A significantly higher prevalence of all five virulence genes was observed in diabetic isolates (<i>fimH</i> OR = 2.63; <i>hlyA</i> OR = 3.17; <i>usp</i> OR = 3.57; <i>traT</i> OR = 3.31; <i>papC</i> OR = 3.45; p &lt; 0.001). Several mutations were identified, with PROVEAN predicting deleterious mutations including V20G (FimH), S130L (HlyA), G3R (USP), G1V and Q104L (PapC), and E27K (TraT). Structural modeling revealed localized conformational shifts, while InterProScan indicated conserved functional domains. Phylogenetic analysis showed that mutated genes formed distinct clusters, pointing to evolutionary divergence. This study emphasizes the value of molecular monitoring and the development of targeted therapies to control antibiotic-resistant <i>E. coli</i> infections in diabetic patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Integrative Molecular and Structural Profiling of Escherichia coli Virulence Genes in Diabetes-Associated Infections

  • 期刊论文

  • 发表日期：

    2026年2月21日

查看全文
  • Noor Jahan Begum,
  • Muhammad Qasim,
  • Ihtisham Ul Haq,
  • Hassan Naveed,
  • Farhan Anwar Khan,
  • Zahid Ullah Khan,
  • Farman Ullah Dawar

摘要

Escherichia coli (E. coli) is a leading cause of urinary tract infections (UTIs) and diabetic foot ulcers, especially in individuals with weakened immune systems. Pathogenic strains (PEC) employ virulence genes including fimH, hlyA, usp, traT, and papC to establish infection, evade immune responses, and cause tissue damage. However, despite its clinical significance, there is a lack of integrative studies profiling virulence genes and identifying mutations in PEC, which may contribute to pathogenicity, antimicrobial resistance, and limitations in targeted therapy. In this study, 210 E. coli isolates were collected from diabetic patients with UTIs or foot ulcers at Hayatabad Medical Complex (HMC), Peshawar. Identification was performed through biochemical profiling and confirmed via PCR targeting 16S rRNA. Antibiotic resistance was assessed using the Kirby-Bauer disk diffusion method. The presence of virulence genes was detected by PCR, and sequencing data were analyzed using bioinformatics tools such as Multiple Sequence Alignment, PROVEAN, InterProScan, and SWISS-MODEL. A significantly higher prevalence of all five virulence genes was observed in diabetic isolates (fimH OR = 2.63; hlyA OR = 3.17; usp OR = 3.57; traT OR = 3.31; papC OR = 3.45; p < 0.001). Several mutations were identified, with PROVEAN predicting deleterious mutations including V20G (FimH), S130L (HlyA), G3R (USP), G1V and Q104L (PapC), and E27K (TraT). Structural modeling revealed localized conformational shifts, while InterProScan indicated conserved functional domains. Phylogenetic analysis showed that mutated genes formed distinct clusters, pointing to evolutionary divergence. This study emphasizes the value of molecular monitoring and the development of targeted therapies to control antibiotic-resistant E. coli infections in diabetic patients.